Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-05-30 Sale |
2024-05-30 6:22 pm |
Inhibrx Inc. | INBX | Lappe Mark Chief Executive Officer |
3,045,654 | $30 | $91,369,620 | 0 (Indirect Direct) |
View |
| 2024-05-30 Sale |
2024-05-30 6:22 pm |
Inhibrx Inc. | INBX | Kayyem Jon Faiz Director |
3,274,301 | $30 | $98,229,030 | 0 (Indirect Direct) |
View |
| 2024-05-30 Sale |
2024-05-30 6:22 pm |
Inhibrx Inc. | INBX | FORSYTH DOUGLAS Director |
598,257 | $30 | $17,947,710 | 0 (Indirect Direct) |
View |
| 2024-05-28 Sale |
2024-05-30 6:21 pm |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
2,355,553 | $30.55 | $71,956,590 | 0 (Indirect Direct) |
View |
| 2023-08-28 Purchase |
2023-08-30 8:44 pm |
Inhibrx Inc. | INBX | VIKING GLOBAL INVESTORS LP Viking Global Opportunities GP LLC Viking Global Opportunities Parent GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner |
511,627 | $19.35 | $9,899,982 | 8,189,591 (Indirect) |
View |
| 2023-03-01 Sale |
2023-03-02 4:17 pm |
Inhibrx Inc. | INBX | Eckelman Brendan P. Eckelman Living Trust Dated February 5 2014 Chief Scientific Officer |
40,000 | $24.21 | $968,231 | 2,355,553 (Indirect) |
View |
| 2023-02-28 Sale |
2023-03-01 4:41 pm |
Inhibrx Inc. | INBX | Lappe Mark Lappe Family Trust Chief Executive Officer |
60 | $25.02 | $1,501 | 3,045,654 (Indirect) |
View |
| 2023-02-01 Sale |
2023-02-02 7:26 pm |
Inhibrx Inc. | INBX | Eckelman Brendan P. Eckelman Living Trust Dated February 5 2014 Chief Scientific Officer |
40,000 | $24.93 | $997,210 | 2,395,553 (Indirect) |
View |
| 2023-01-23 Sale |
2023-01-24 6:46 pm |
Inhibrx Inc. | INBX | Lappe Mark Lappe Family Trust Chief Executive Officer |
26,000 | $25.42 | $660,842 | 3,045,714 (Indirect) |
View |
| 2023-01-23 Sale |
2023-01-23 6:10 pm |
Inhibrx Inc. | INBX | Kayyem Jon Faiz Director |
9,500 | $25.26 | $239,999 | 3,274,301 (Indirect) |
View |
| 2023-01-03 Sale |
2023-01-04 5:53 pm |
Inhibrx Inc. | INBX | Eckelman Brendan P. Eckelman Living Trust Dated February 5 2014 Chief Scientific Officer |
40,000 | $23.71 | $948,598 | 2,475,553 (Indirect Direct) |
View |
| 2022-12-21 Sale |
2022-12-22 4:04 pm |
Inhibrx Inc. | INBX | Kayyem Jon Faiz Director |
9,500 | $27.02 | $256,679 | 3,283,801 (Indirect) |
View |
| 2022-12-19 Sale |
2022-12-20 4:59 pm |
Inhibrx Inc. | INBX | Lappe Mark Lappe Family Trust Chief Executive Officer |
26,000 | $25.56 | $664,443 | 3,071,714 (Indirect) |
View |
| 2022-12-06 Sale |
2022-12-07 4:30 pm |
Inhibrx Inc. | INBX | Eckelman Brendan P. Eckelman Living Trust Dated February 5 2014 Chief Scientific Officer |
40,000 | $27.22 | $1,088,683 | 2,475,553 (Indirect) |
View |
| 2022-11-21 Sale |
2022-11-22 4:42 pm |
Inhibrx Inc. | INBX | Kayyem Jon Faiz Director |
9,500 | $29.89 | $283,972 | 3,293,301 (Indirect) |
View |
| 2022-11-17 Sale |
2022-11-18 5:06 pm |
Inhibrx Inc. | INBX | Lappe Mark Lappe Family Trust Chief Executive Officer |
26,000 | $27.88 | $724,910 | 3,097,714 (Indirect) |
View |
| 2022-11-01 Sale |
2022-11-02 5:04 pm |
Inhibrx Inc. | INBX | Eckelman Brendan P. Eckelman Living Trust Dated February 5 2014 Chief Scientific Officer |
40,000 | $33.51 | $1,340,387 | 2,515,553 (Indirect) |
View |
| 2022-10-21 Sale |
2022-10-24 4:36 pm |
Inhibrx Inc. | INBX | Kayyem Jon Faiz Director |
9,500 | $30.13 | $286,232 | 3,302,801 (Indirect) |
View |
| 2022-10-17 Sale |
2022-10-18 4:37 pm |
Inhibrx Inc. | INBX | Lappe Mark Lappe Family Trust Chief Executive Officer |
26,000 | $29.59 | $769,443 | 3,123,714 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-05-30 Other |
2024-06-03 5:55 pm |
N/A N/A |
Inhibrx Inc. | INBX | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Parent GP LLC Viking Global Opportunities GP LLC Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities Illiquid Investments Sub-Master LP HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner |
8,189,591 | $30 | 7,150,826 (Indirect) |
View |
| 2024-05-29 Other |
2024-05-31 4:30 pm |
N/A N/A |
Inhibrx Biosciences Inc. | INBX | Inhibrx Inc. 10% Owner |
13,316,140 | $0 | 14,474,066 (Direct) |
View |
| 2024-05-22 Exercise |
2024-05-24 6:15 pm |
N/A 2031-01-15 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
5,010 | $34.12 | 33,334 (Direct) |
View |
Ownership |
2024-05-24 4:44 pm |
N/A N/A |
Inhibrx Biosciences Inc. | INXB | Inhibrx Inc. 10% Owner |
0 | $0 | 100 (Direct) |
View |
| 2024-05-06 Exercise |
2024-05-08 4:57 pm |
N/A 2028-11-26 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
19,711 | $34.24 | 0 (Direct) |
View |
| 2024-03-26 Exercise |
2024-03-28 4:36 pm |
N/A 2028-11-26 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
2,896 | $35.4 | 62,624 (Direct) |
View |
| 2024-03-21 Exercise |
2024-03-22 4:54 pm |
N/A 2028-11-26 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
3,113 | $35.09 | 57,393 (Direct) |
View |
| 2024-03-20 Exercise |
2024-03-22 4:54 pm |
N/A 2028-11-26 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
16,777 | $35.02 | 57,393 (Direct) |
View |
| 2024-03-22 Exercise |
2024-03-22 4:54 pm |
N/A 2028-11-26 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
110 | $35 | 57,393 (Direct) |
View |
| 2024-03-13 Exercise |
2024-03-15 4:48 pm |
N/A 2031-01-15 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
1,898 | $35.33 | 9,177 (Direct) |
View |
| 2024-03-13 Exercise |
2024-03-15 4:46 pm |
N/A 2030-04-21 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
32,431 | $35.43 | 2,087 (Direct) |
View |
| 2024-03-12 Exercise |
2024-03-12 6:04 pm |
N/A 2033-01-03 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
4,152 | $35.25 | 142,384 (Direct) |
View |
| 2024-03-08 Exercise |
2024-03-12 6:04 pm |
N/A 2021-01-15 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
2,150 | $35.75 | 142,384 (Direct) |
View |
| 2024-03-12 Exercise |
2024-03-12 6:04 pm |
N/A 2021-01-15 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
19,898 | $35.25 | 142,384 (Direct) |
View |
| 2024-03-11 Exercise |
2024-03-12 6:04 pm |
N/A 2033-01-03 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
6,681 | $35.33 | 142,384 (Direct) |
View |
| 2024-03-11 Exercise |
2024-03-12 6:04 pm |
N/A 2021-01-15 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Chief Scientific Officer |
6,877 | $35.3 | 142,384 (Direct) |
View |
| 2024-03-08 Exercise |
2024-03-12 4:20 pm |
N/A 2028-11-26 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
42,523 | $35.75 | 38,020 (Direct) |
View |
| 2024-03-04 Exercise |
2024-03-06 4:41 pm |
N/A 2033-01-03 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
8,125 | $35.6 | 47,500 (Direct) |
View |
| 2024-03-04 Exercise |
2024-03-06 4:41 pm |
N/A 2031-01-15 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
53,958 | $35.4 | 47,500 (Direct) |
View |
| 2024-03-05 Exercise |
2024-03-06 4:41 pm |
N/A 2032-01-11 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
10,417 | $35.72 | 47,500 (Direct) |
View |
| 2023-05-25 Option Award |
2023-05-30 4:12 pm |
N/A 2033-05-25 |
Inhibrx Inc. | INBX | FORSYTH DOUGLAS Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2023-05-25 Option Award |
2023-05-30 4:10 pm |
N/A 2033-05-25 |
Inhibrx Inc. | INBX | Vuori Kristiina MD Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2023-05-25 Option Award |
2023-05-30 4:08 pm |
N/A 2033-05-25 |
Inhibrx Inc. | INBX | MANHARD KIMBERLY Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2023-05-25 Option Award |
2023-05-30 4:07 pm |
N/A 2033-05-25 |
Inhibrx Inc. | INBX | Kayyem Jon Faiz Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-04 5:53 pm |
N/A 2033-01-03 |
Inhibrx Inc. | INBX | Eckelman Brendan P. Eckelman Living Trust Dated February 5 2014 Chief Scientific Officer |
40,000 | $0 | 2,475,553 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-03 6:11 pm |
N/A 2033-01-03 |
Inhibrx Inc. | INBX | Lappe Mark Chief Executive Officer |
100,000 | $0 | 100,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-03 6:09 pm |
N/A 2033-01-03 |
Inhibrx Inc. | INBX | Deck Kelly Chief Financial Officer |
30,000 | $0 | 30,000 (Direct) |
View |